NO20034185D0 - Nikotinreseptorantagonister for behandling av inflammatoriske sykdommer - Google Patents

Nikotinreseptorantagonister for behandling av inflammatoriske sykdommer

Info

Publication number
NO20034185D0
NO20034185D0 NO20034185A NO20034185A NO20034185D0 NO 20034185 D0 NO20034185 D0 NO 20034185D0 NO 20034185 A NO20034185 A NO 20034185A NO 20034185 A NO20034185 A NO 20034185A NO 20034185 D0 NO20034185 D0 NO 20034185D0
Authority
NO
Norway
Prior art keywords
agonists
pulmonary
nicotine receptor
diseases
inflammatory diseases
Prior art date
Application number
NO20034185A
Other languages
English (en)
Other versions
NO331674B1 (no
NO20034185L (no
Inventor
Yvon Cormier
Evelyne Israel-Assayag
Marie-Renee Blanchet
Original Assignee
Univ Laval
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Laval filed Critical Univ Laval
Publication of NO20034185D0 publication Critical patent/NO20034185D0/no
Publication of NO20034185L publication Critical patent/NO20034185L/no
Publication of NO331674B1 publication Critical patent/NO331674B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20034185A 2001-03-23 2003-09-19 Farmasoytisk sammensetning omfattende nikotinreseptorantagonist for lindring eller forebygging av pulmonaer inflammatorisk sykdom NO331674B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002341952A CA2341952A1 (en) 2001-03-23 2001-03-23 Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases
PCT/CA2002/000412 WO2002076434A2 (en) 2001-03-23 2002-03-25 Nicotinic receptor agonists for the treatment of inflammatory diseases

Publications (3)

Publication Number Publication Date
NO20034185D0 true NO20034185D0 (no) 2003-09-19
NO20034185L NO20034185L (no) 2003-11-24
NO331674B1 NO331674B1 (no) 2012-02-20

Family

ID=4168679

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20034185A NO331674B1 (no) 2001-03-23 2003-09-19 Farmasoytisk sammensetning omfattende nikotinreseptorantagonist for lindring eller forebygging av pulmonaer inflammatorisk sykdom

Country Status (18)

Country Link
US (3) US7601720B2 (no)
EP (1) EP1370264B1 (no)
JP (1) JP4377586B2 (no)
CN (1) CN100528159C (no)
AT (1) ATE378051T1 (no)
AU (1) AU2002249023B2 (no)
BR (1) BR0208305A (no)
CA (1) CA2341952A1 (no)
DE (1) DE60223508T2 (no)
DK (1) DK1370264T3 (no)
ES (1) ES2295331T3 (no)
IL (1) IL157757A0 (no)
MX (1) MXPA03008423A (no)
NO (1) NO331674B1 (no)
NZ (1) NZ528042A (no)
PL (1) PL207880B1 (no)
RU (1) RU2299731C2 (no)
WO (1) WO2002076434A2 (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8188043B2 (en) 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
CA2341952A1 (en) 2001-03-23 2002-09-23 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases
US20050130990A1 (en) * 2001-03-23 2005-06-16 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
US7045534B2 (en) * 2002-02-12 2006-05-16 The Board Of Trustees Of The Leland Stanford Junior University Methods of reducing angiogenesis
US8039459B2 (en) 2004-07-15 2011-10-18 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
US8557804B2 (en) 2002-03-25 2013-10-15 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
US20040010018A1 (en) * 2002-05-15 2004-01-15 Rueter Lynne E. Treatment of neuropathic pain
US7238715B2 (en) 2002-12-06 2007-07-03 The Feinstein Institute For Medical Research Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
PL364348A1 (en) 2004-01-12 2005-07-25 PHARMENA Sp.z o.o. Application of quaternary pyridine salts as vessel protection agent
NZ553211A (en) * 2004-07-15 2010-11-26 Univ Laval Nicotinic receptor agonists for the treatment of pulmonary inflammatory diseases
US8378109B2 (en) 2004-12-07 2013-02-19 The Regents Of The University Of California Labeled ALPHA4BETA2 ligands and methods therefor
US9029557B2 (en) 2004-12-07 2015-05-12 The Regents Of The University Of California Labeled A4B2 ligands and methods therefor
US8316104B2 (en) 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system
JP2009519962A (ja) * 2005-12-19 2009-05-21 コメンティス，インコーポレーテッド 眼投与用局所メカミルアミン製剤およびその使用
WO2007129879A1 (es) * 2006-05-08 2007-11-15 Arturo Solis Herrera EL USO DE LA NICOTINA, SUS ANÁLOGOS, SUS PRECURSORES O SUS DERIVADOS EN EL TRATAMIENTO DE DIVERSOS PROCESOS PATOLÓGICOS SUSCEPTIBLES DE MEJORAR CON α-MSH ADMINISTRADA EN FORMA PROFILÁCTICA O TERAPÉUTICA.
EP3524245A1 (en) * 2010-03-23 2019-08-14 Philip Morris Products S.A. Use of anatabine to treat inflammation and methods of synthesizing anatabine
US8207346B2 (en) 2010-03-23 2012-06-26 Rock Creek Pharmaceuticals, Inc. Methods of synthesizing anatabine
JP5934796B2 (ja) 2011-08-29 2016-06-15 アールシーピー ディベロップメント インコーポレイテッド 抗炎症補助のための製品
EP3125903B1 (en) 2014-04-03 2018-12-19 Université Laval Method for use of homopiperazinium compounds in the treatment of cancer
RU2593585C1 (ru) * 2015-06-26 2016-08-10 Общество с ограниченной ответственностью "Ритек-Фарма" Способ лечения табакокурения и других форм никотиновой зависимости, а также профилактики рецидивов табакокурения
CN113992687B (zh) * 2021-12-28 2022-04-08 浙江宇视科技有限公司 智能业务集群调度方法、装置、电子设备及存储介质

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2594296A (en) * 1948-06-24 1952-04-29 Aerosol Corp Lobeline aerosol dilating medicament
US2778772A (en) * 1952-11-04 1957-01-22 Parke Davis & Co Dimethyl phenyl piperazinium iodide compositions and process for stimulation of the autonomic ganglion system
US3402039A (en) * 1966-12-05 1968-09-17 Dow Chemical Co Piperazinium salts as plant stunting agents
US5977144A (en) * 1992-08-31 1999-11-02 University Of Florida Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
US5856480A (en) * 1994-11-11 1999-01-05 Nippon Soda Co., Ltd. Optically active compound
WO2000023062A2 (en) * 1998-10-20 2000-04-27 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain and inflammation
US5846983A (en) 1996-02-09 1998-12-08 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
RU2127123C1 (ru) * 1996-06-04 1999-03-10 Московское производственное химико-фармацевтическое объединение им.Н.А.Семашко Противоастматическое лекарственное средство в виде таблеток и способ получения таблеток
GB9614902D0 (en) * 1996-07-16 1996-09-04 Rhodes John Sustained release composition
US5981549A (en) * 1997-02-14 1999-11-09 Synapse Pharmaceutical International Method for controlling or alleviating the symptoms of respiratory disease and allergies
WO1999021834A1 (en) 1997-10-27 1999-05-06 Neurosearch A/S Heteroaryl diazacycloalkanes as cholinergic ligands at nicotinic acetylcholine receptors
CA2364026C (en) * 1999-03-02 2012-08-21 Centocor, Inc. Anti-tnf.alpha. antibodies in therapy of asthma
JP2003502374A (ja) * 1999-06-21 2003-01-21 ブリストルーマイヤーズ スクイブ カンパニー Ｎｐｙ拮抗薬としてのジヒドロピラジン誘導体
SE0001075D0 (sv) * 1999-09-01 2000-03-27 Laszlo Bense Användning av åtminstone ett nikotinbaserat ämne och/eller ett ur detta ämne framställt ämne för tillverkning av ett medikament samt förfarande för behandling av obstruktiva lungsjukdomar
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
US6610713B2 (en) * 2000-05-23 2003-08-26 North Shore - Long Island Jewish Research Institute Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
JP2004514722A (ja) * 2000-12-01 2004-05-20 ニューロサーチ、アクティーゼルスカブ ３−置換されたキヌクリジン及びこれをニコチンアンタゴニストとして使用する方法
US20020160988A1 (en) * 2001-02-20 2002-10-31 Israel Institute For Biological Research Compounds co-inducing cholinergic up-regulation and inflammation down-regulation and uses thereof
WO2002076424A1 (en) 2001-03-22 2002-10-03 Battelle Memorial Institute Liquid formations for electrohydrodymanic spraying containing polymer and suspended particles
CA2341952A1 (en) 2001-03-23 2002-09-23 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases
US20050130990A1 (en) * 2001-03-23 2005-06-16 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
US6667344B2 (en) * 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
GB2381750A (en) 2001-10-10 2003-05-14 Inspire Pharmaceuticals Inc Treatment for enhancing joint lubrication
US20030236287A1 (en) * 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor
TW200412945A (en) * 2002-10-25 2004-08-01 Upjohn Co Quaternary ammonium compounds
CA2498189A1 (en) * 2002-10-29 2004-05-13 Pharmacia & Upjohn Company Llc Quaternary ammonium compounds
JP2006506392A (ja) * 2002-10-29 2006-02-23 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー ムスカリン受容体アンタゴニストとしての第四級アンモニウム化合物
US20050075323A1 (en) * 2003-03-05 2005-04-07 Pfizer Inc Beta3 adrenergic receptor agonists and uses thereof
FR2852830B1 (fr) 2003-03-24 2008-04-18 Oreal Composition de teinture des fibres keratiniques comprenant un derive de para-phenylenediamine cationique substitue par un cycle diazacyclohexane ou diazacycloheptane
MXPA05011059A (es) * 2003-04-15 2005-12-12 Pharmacia & Upjohn Co Llc Compuestos de amonio cuaternario y su uso como agentes antimuscarinicos.
NZ553211A (en) 2004-07-15 2010-11-26 Univ Laval Nicotinic receptor agonists for the treatment of pulmonary inflammatory diseases

Also Published As

Publication number Publication date
ATE378051T1 (de) 2007-11-15
CN1498108A (zh) 2004-05-19
DK1370264T3 (da) 2008-03-17
EP1370264A2 (en) 2003-12-17
US20100227871A1 (en) 2010-09-09
NZ528042A (en) 2005-10-28
PL207880B1 (pl) 2011-02-28
BR0208305A (pt) 2004-03-09
ES2295331T3 (es) 2008-04-16
MXPA03008423A (es) 2004-03-19
IL157757A0 (en) 2004-03-28
CN100528159C (zh) 2009-08-19
EP1370264B1 (en) 2007-11-14
NO331674B1 (no) 2012-02-20
RU2003131178A (ru) 2005-04-10
WO2002076434A2 (en) 2002-10-03
US20110245270A1 (en) 2011-10-06
PL365224A1 (en) 2004-12-27
NO20034185L (no) 2003-11-24
US7601720B2 (en) 2009-10-13
CA2341952A1 (en) 2002-09-23
JP2004523588A (ja) 2004-08-05
RU2299731C2 (ru) 2007-05-27
US8377936B2 (en) 2013-02-19
US20040132737A1 (en) 2004-07-08
WO2002076434A3 (en) 2003-07-17
DE60223508D1 (de) 2007-12-27
AU2002249023B2 (en) 2006-02-02
DE60223508T2 (de) 2008-09-25
JP4377586B2 (ja) 2009-12-02

Similar Documents

Publication Publication Date Title
NO20034185L (no) Nikotinreseptorantagonister for behandling av inflammatoriske sykdommer
DE60120936D1 (de) Behandlung von atemerkrankungen
ATE330589T1 (de) Pharmazeutische zusammensetzung enthaltend resveratrol zur behandlung von entzündlichen erkrankungen der atemwege
JP2017528507A5 (no)
EA200702387A1 (ru) Имидазохинолины в качестве ингибиторов липидкиназы
WO2004041183A3 (en) Methods of treating pulmonary fibrotic disorders
NO20072466L (no) Fremgangsmate for a forhindre og behandle strukturendring i luftveier og pulmonal inflammasjon ved a anvende A2B-adenosinreseptorantagonister
MXPA03010731A (es) Combinacion de agonista del receptor a2a de adenosina y tiotropio o sus derivados para tratar enfermedades obstructivas de vias aereas.
WO2005107726A3 (en) Method for the treatment of back pain
SG169233A1 (en) Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
EP2269610A3 (en) Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
WO2005000298A3 (en) 5-membered heterocycle-based p-38 inhibitors
TW200738729A (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
MX2021014157A (es) Formas cristalinas de un inhibidor btk.
NO20074084L (no) Substituerte 4-fenyltetrahydroisokinoliner, fremgangsmate for fremstilling derav, deres anvendelse som medikamenter og medikamenter inneholdende disse
BR0313718A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, métodos para tratar um indivìduo humano ou animal sofrendo de uma condição que é mediada por cox-2 e para tratar um indivìduo humano ou animal sofrendo de um distúrbio inflamatório, e, uso de um composto
WO2006012640A3 (en) Method of administration of dopamine receptor agonists
JP2017536380A5 (no)
JOP20200314A1 (ar) تركيبات صيدلانية مستقرة لأجهزة إستنشاق جرعات مضغوطة معايرة الجرعة
UY30935A1 (es) Combinacion:-antagonista del receptor de quimioquina 1 (ccr1) -agonista del receptor de glucocorticoides- opcionalmente agonista b(beta)2, -composicion farmacéutica conteniéndola -aplicaciones.
WO2004056310A3 (en) Methods of diagnosis and treatment of interstitial lung disease
EA200200518A1 (ru) Способ и композиция для лечения заболеваний легких
HUP0401967A2 (hu) Nikotinsav-acetilkolin-receptor-agonisták alkalmazása nyugtalan láb szindróma kezelésére alkalmas gyógyszerkészítmények előállítására
JP2007506726A5 (no)
MX2023005801A (es) Derivados de ftalazina como inhibidores de purinoceptor 3 de p2x (p2x3).

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees